CAR-T therapy shows promise in rare childhood neuroblastoma

Written by Rachel Jenkins, Future Science Group

CAR-T cell therapy

Researchers from the University College London (UCL; UK) have developed a CAR-T therapy designed to target cancerous tumors. The novel therapy has shown promising results in children with neuroblastoma. The study modified neuroblastoma patient’s own T cells, equipping them to recognize and kill neuroblastoma tumor cells. Recently published in Science Translational Medicine, a total of 12 children with relapsed or refractory neuroblastoma were treated as part of the Phase I trial. The patients’ own T cells were modified with a CAR to target the GD2 surface protein, which is abundant on almost all neuroblastoma cells. When using a sufficient dose...

To view this content, please register now for access

It's completely free